Clinical Data 23andMe study explains variable results with obesity drugs PharmaphorumGene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.Clinical DataMetabolic & GLP-1Read full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaphorum Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: EverSea Medicines to acquire Hasten BiopharmaceuticalsNext: The FTC Blows Up Express Scripts’ PBM Model–and Launches the Net Pricing Drug Channel (rerun) Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026